The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Venetoclax and rituximab: changing the treatment landscape in R/R CLL
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany, talks to us about exciting new data for the venetoclax and rituximab combination in the MURANO Phase III trial (NCT02005471) for relapsed/refractory chronic lymphocytic leukemia (CLL). Results published earlier this year presented positive results for progression-free and overall survival. Now, an update on response rates, particularly minimal residual disease (MRD) negativity rates, have been released. Dr Eichorst discusses this data, which showed higher MRD negativity rates with venetoclax and rituximab therapy for both treatment arms.The recent approval of venetoclax plus rituximab leads to curiosity about how this will influence the sequence and choice of treatment in CLL. This interview was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
